Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul 3;27(7):1213-1214.
doi: 10.1016/j.ymthe.2019.06.001. Epub 2019 Jun 13.

Fresh versus Frozen: Effects of Cryopreservation on CAR T Cells

Patrick J Hanley  1
Affiliations
Comment

Fresh versus Frozen: Effects of Cryopreservation on CAR T Cells

Patrick J Hanley. Mol Ther. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Panch S.R., Srivastava S.K., Elavia N., McManus A., Liu S., Jin P., Highfill S.L., Li X., Dagur P., Kochenderfer J. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Mol. Ther. 2019;27:1275–1285. this issue. - PMC - PubMed
    2. Panch, S.R., Srivastava, S.K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S.L., Li, X., Dagur, P., Kochenderfer, J., et al. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Mol. Ther. 27, this issue, ▪▪▪–▪▪▪. - PMC - PubMed
    1. Chong E.A., Levine B., Grupp S.A., Davis M., Siegel D.L., Maude S.L., Gladney W.L., Frey N.V., Porter D.L., June C.H., Schuster S.J. CD19-Directed CAR T-cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia. Blood. 2018;132(Suppl 1):197. - PubMed
    2. Chong, E.A., Levine, B., Grupp, S.A., Davis, M., Siegel, D.L., Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., June, C.H., and Schuster, S.J. (2018). CD19-Directed CAR T-cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia. Blood 132 (Suppl 1), 197.
    1. Tanna J.G., Ulrey R., Williams K.M., Hanley P.J. Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells. Cytotherapy. 2019;21:278–288. - PubMed
    2. Tanna, J.G., Ulrey, R., Williams, K.M., and Hanley, P.J. (2019). Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells. Cytotherapy 21, 278-288. - PubMed
    1. Hopewell E.L., Cox C., Pilon-Thomas S., Kelley L.L. Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy. 2019;21:307–314. - PMC - PubMed
    2. Hopewell, E.L., Cox, C., Pilon-Thomas, S., and Kelley, L.L. (2019). Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy 21, 307-314. - PMC - PubMed
    1. Roddie C., O’Reilly M., Dias Alves Pinto J., Vispute K., Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21:327–340. - PubMed
    2. Roddie, C., O’Reilly, M., Dias Alves Pinto, J., Vispute, K., and Lowdell, M. (2019). Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy 21, 327-340. - PubMed

Substances

LinkOut - more resources